Sonoma Pharmaceuticals Reports Director and Officer Changes
Ticker: SNOA · Form: 8-K · Filed: Jan 3, 2025 · CIK: 1367083
Sentiment: neutral
Topics: management-change, corporate-governance
Related Tickers: SONM
TL;DR
Sonoma Pharma (SONM) board shakeup effective Jan 2nd.
AI Summary
Sonoma Pharmaceuticals, Inc. filed an 8-K on January 3, 2025, reporting changes effective January 2, 2025. The filing covers the departure and election of directors, appointment of officers, and compensatory arrangements for certain officers. The company was formerly known as Oculus Innovative Sciences, Inc. and is incorporated in Delaware.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty regarding future company direction and performance.
Key Numbers
- 001-33216 — SEC File Number (Identifies the company's filing with the SEC)
- 68-0423298 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Sonoma Pharmaceuticals, Inc. (company) — Registrant
- Oculus Innovative Sciences, Inc. (company) — Former company name
- January 2, 2025 (date) — Effective date of reported changes
- January 3, 2025 (date) — Filing date of the 8-K
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific changes were made to the board of directors?
The filing indicates the departure and election of directors, but the specific names and details of these changes are not provided in this excerpt.
Who are the newly appointed officers?
The filing mentions the appointment of certain officers, but their identities are not specified in this document excerpt.
What are the details of the compensatory arrangements for the officers?
The filing notes that compensatory arrangements for certain officers are covered, but the specifics are not detailed in this provided text.
When did the reported changes become effective?
The changes reported in the 8-K became effective on January 2, 2025.
What was Sonoma Pharmaceuticals, Inc. previously named?
Sonoma Pharmaceuticals, Inc. was formerly known as Oculus Innovative Sciences, Inc.
Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-01-03 17:00:33
Key Financial Figures
- $2.68 — he closing price of our common stock of $2.68 per share on January 2, 2025, and the o
Filing Documents
- sonoma_8k.htm (8-K) — 29KB
- 0001683168-25-000076.txt ( ) — 200KB
- snoa-20250102.xsd (EX-101.SCH) — 3KB
- snoa-20250102_lab.xml (EX-101.LAB) — 33KB
- snoa-20250102_pre.xml (EX-101.PRE) — 24KB
- sonoma_8k_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 2, 2025, we completed our annual equity grant to employees, including executive officers, of the Company. The annual grant is intended to recognize employees who meet certain employment criteria and to retain key employees. The Company's non-employee directors each received 7,500 options. The exercise price of the options is based on the closing price of our common stock of $2.68 per share on January 2, 2025, and the options vest in three equal tranches on the first, second and third anniversary of the grant date. Each executive officer received Restricted Stock Units (RSUs) as follows: Amy Trombly, Chief Executive Officer: 10,000 RSUs; Jerry Dvonch, Chief Financial Officer: 10,000 RSUs; and Bruce Thornton, Executive Vice President and Chief Operating Officer: 10,000 RSUs. The RSUs vest in three equal tranches 6, 18 and 24 months from the grant date with a valuation based on the five day weighted-average stock price on the date of vesting. All options and RSUs vest upon change of control and as otherwise provided in an executive officer's employment agreement. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SONOMA PHARMACEUTICALS, INC. Date: January 3, 2025 By: /s/ Amy Trombly Name: Title: Amy Trombly Chief Executive Officer 3